Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This document studied minoxidil in healthy volunteers. Minoxidil is quickly absorbed and eliminated from the body.

This study reviewed literature on low-dose oral minoxidil as a treatment for hair loss, finding good compliance and tolerability, with mild adverse effects like hypertrichosis, which increase with higher doses.

This expert consensus discusses the potential use of oral minoxidil for treating alopecia and provides guidance to clinicians based on a comprehensive literature review and expert feedback; it reports no new clinical results.

In this systematic review, oral minoxidil was found to be a safe and effective treatment for androgenetic alopecia and alopecia areata, with additional benefits for female pattern hair loss and other types of alopecia, although common side effects included hypertrichosis and postural hypotension.

This article reflects on the history and significance of the FDA's approval of topical minoxidil for treating androgenetic alopecia in men and women, dating back to 1988 and 1991 respectively.

Low-dose oral minoxidil increases hair density and thickness in people with hair loss.

In this study, low-dose naltrexone significantly reduced erythema in patients with frontal fibrosing alopecia and lichen planopilaris after one year, but no significant improvements were seen in other symptoms.

This commentary highlights the consistency of recent findings on low-dose oral minoxidil's tolerability for androgenetic alopecia, noting infrequent side effects except for hypertrichosis.

In this randomized controlled trial, researchers found that a 2.5 mg daily dose of oral minoxidil was more effective than a 1 mg dose in improving hair growth parameters in patients with androgenetic alopecia over three months, with both doses being well tolerated.

Low-dose oral minoxidil may be a promising alternative to topical minoxidil for hair loss.

Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.

This study highlights the diverse prescribing and monitoring practices for low-dose oral minoxidil among dermatologists in the UK and Ireland, used widely for various hair loss conditions both as monotherapy and adjunctive therapy.

This article discusses the rising use of low-dose oral minoxidil for androgenetic alopecia and mentions common side effects like hypertrichosis, but provides no new clinical findings.

The study explores the potential effectiveness of low-dose oral minoxidil in treating short anagen hair syndrome, suggesting it may be a viable treatment option despite the condition often resolving spontaneously with puberty.

This study found that adding low-dose oral minoxidil to standard treatment for lichen planopilaris was safe but did not significantly improve hair density or thickness, although minor hair regrowth was observed in some scarring areas.

This consensus statement provides expert guidance on prescribing low-dose oral minoxidil for hair loss, noting a lack of representation of pediatric specialists and highlighting areas for future research.

This review discusses the consensus reached by international experts on guidelines for prescribing and monitoring low-dose oral minoxidil for hair loss, and reports no new clinical results.

This case study involving a 63-year-old woman with female pattern hair loss found that a 3-month regimen of low-dose oral minoxidil increased hair density from 98 to 140 hairs per square centimeter, but caution was advised regarding its safety and efficacy without larger trials.

Low-dose oral minoxidil is generally safe for hypertensive patients with hair loss.

Low-dose oral minoxidil is safe for alopecia patients, even those prone to edema.

This study found that combining platelet-rich plasma with topical minoxidil led to the greatest increase in terminal hair density at 32 weeks, while low-dose oral minoxidil was more effective at reducing vellus hair density in men with androgenetic alopecia.

The study found that combining platelet-rich plasma with topical minoxidil significantly improved terminal hair density in androgenetic alopecia patients, while low-dose oral minoxidil was more effective at reducing vellus hair density.

Among Saudi dermatologists, this study reported widespread recognition of low-dose oral minoxidil's use for patterned hair loss and its side effect of hypertrichosis; however, many avoid prescribing it due to its unavailability in local pharmacies.

This letter highlights the lack of evidence on managing persistent alopecia induced by chemotherapy and endocrine therapy in breast cancer patients, noting that prior studies have not included endocrine therapy-induced alopecia.

This case report describes successful treatment with low-dose oral minoxidil for endocrine therapy-induced alopecia in a breast cancer patient unresponsive to topical minoxidil.

Low-dose oral minoxidil is a promising, safe treatment for various hair diseases, improving hair thickness and density, but more research is needed on long-term side effects and treatment duration.

This study found that corticosteroid pulse therapy may be more effective than oral cyclosporine with corticosteroid for patients with severe alopecia areata, especially for those with the plurifocal type or a short disease duration.

This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.

This study found that in healthy young men, oral minoxidil at 5 mg/day led to increased carotid intima-media thickness and vascular aging, suggesting potential cardiovascular side effects at higher doses. A dose-dependent effect was observed, while dutasteride displayed a favorable vascular profile without significant changes.

This systematic review reported that while combining low-dose oral minoxidil with Janus kinase inhibitors may enhance treatment outcomes in alopecia areata, the evidence remains weak due to limited sample sizes and potential publication bias, and more rigorous trials are necessary to assess efficacy and safety.